Finally, according to what proposed for ALK inhibition by targeted therapy [36], the new finding of a concurrent involvement of ALK and PHOX2B genes in NB initiation and progression opens new perspectives on the design of innovative therapeutic RNAi-mediated strategies to knock-down multiple target genes and is expected to have a fundamental impact for this ominous pediatric tumor, which is often refractory to conventional therapies. Here, PHOX2B is linked to neoplasm.